AI Era Evidence Flywheel

Key Concepts

Episode Summary

• check_circleThe pharmaceutical industry's traditional approach to drug discovery is flawed, with a high failure rate and massive costs.
• check_circleAI was initially seen as a way to accelerate the process, but this approach has been flawed.
• check_circleA new approach is needed, focusing on reducing biological uncertainty and using AI to design molecules that fit specific targets.
• check_circleThe 5R framework is a successful attempt to formalize discipline in drug discovery, focusing on the right target, tissue, safety, patient, and commercial potential.
• check_circleHuman genetics play a crucial role in identifying causal relationships between targets and diseases.
• check_circleAI structural tools like AlphaFold2 and AlphaFold3 have dominated the headlines, but their use in drug discovery requires a strict warning.
• check_circleProtein structures must be treated as dynamic hypotheses, not absolute biological reality.
• check_circleEnsemble modeling is a key approach in AI-era drug design, using molecular dynamic simulations to generate hundreds of possible conformational states.
• check_circleThe AI has to design a molecule that remains effective across the entire dynamic landscape.
• check_circlePareto optimization is used to balance competing physical properties, such as potency and solubility.
• check_circleSafety must be front-loaded as a day zero design constraint, with the AI predicting toxicity pathways before the physical molecule exists.

Full Transcript